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Abstract  
2 
Metabolic syndrome (MS) is a complex disorder defined by a cluster of interconnecting 
factors including obesity, diabetes, lipedema, hypertension, macro- and micro-vascular 
complications, and atherosclerosis. Although individual and genetic factors could influence the 
onset and severity of MS, the major causative factor for MS is the excessive intake of calorie, 
partly related to the western-style-diets which contains high amount of fat and carbohydrate 
spreading across the world.  
Fatty acids are the major constituent of lipids, and utilized not only as an essential energy 
source for human health, but also contributes as a comportment of cell membrane, cholesterol 
ester, precursor of eicosanoids, ligand for nuclear receptors and G-protein coupled receptors 
(GPCR), as well as barrier function in epidermal. Therefore, I considered that basic research 
of fatty acids-mediated signals related to the onset of MS are worthy for the disease 
understanding and future drug discovery. Here, I report the physiological importance of delta-
5-desaturase (D5D) mediated fatty acids metabolism on the obesity and insulin resistance 
(Chapter 1), and G-protein coupled receptor 40 (GPR40) signals on the glucose mediated 
insulin secretion from the pancreatic β-cells (Chapter 2). 
 
Chapter 1: D5D activity is important for the development of insulin resistance and obesity.  
D5D is an enzyme that metabolizes dihomo-γ-linolenic acid (DGLA; precursor to anti-
inflammatory eicosanoids) to arachidonic acid (AA; precursor to pro-inflammatory 
eicosanoids). Thus, I used a D5D specific inhibitor, compound-326, to demonstrate the 
physiological importance of the enzyme on the development of MS using a high-fat diet 
induced obese (DIO) mouse model. In vivo D5D inhibition was confirmed by determining 
changes in blood AA/DGLA profiles. In DIO mice, chronic treatment with D5D inhibitor 
lowered insulin resistance and caused body weight loss without significant impact on 
cumulative calorie intake. Decreased macrophage infiltration into the adipose tissue was 
3 
suggested from mRNA analysis. In line with sustained body weight loss, increased daily energy 
expenditure was also observed following the inhibition of D5D.  
 
Chapter 2: GPR40 mediated signal contributes to pancreatic hormone secretion 
GPR40 is known as a GPCR which is activated by free fatty acids (FFA), as its natural 
ligands. To analyze the contribution of GPR40 signal on insulin and glucagon secretion, I 
evaluated the effect of synthetic GPR40 agonist, TAK-875, on hormone secretions using both 
human and rat isolated islets. In both species, stimulation of GPR40 signal enhanced insulin 
secretion in lines with the elevation of β-cell [Ca2+]i in a glucose dependent manner. GPR40 
stimulation did not affect glucagon secretion at both low and high glucose in human islets. 
These data indicate that GPR40 signal mainly influences insulin secretion from pancreatic β-
cell in a glucose-dependent manner. 
These studies reported here clearly support the idea that fatty acids and their metabolites 
play important roles in maintain the physiological functions, and pharmacological intervention 
to fatty acids-mediated signals would be a useful way to tackle the MS.  
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AA arachidonic acid MC  methylcellulose  
ALA α-linolenic acid MCFAs Medium-chain fatty acids  
AU arbitrary units  MS Metabolic syndrome  
AUC area under the curve ND Normal diet  
BAT brown adipose tissue OGTT oral glucose tolerance test  
BSA bovine serum albumin PCR polymerase chain reaction  
CB1 cannabinoid receptor 1 PD pharmacodynamics  
CVD cardiovascular disease  PUFA Longer-chain polyunsaturated fatty acids  
D5D delta-5-desaturase RER  respiratory exchange ratio  
D6D delta-6 desaturase RIA radioimmunoassay  
D9D Delta-9 desaturase SCFAs Short-chain fatty acids  
DGLA dihomo-γ-linolenic acid SUR1 sulfonylurea receptor 1  
DHA  docosahexaenoic acid  T2DM type 2 diabetes  
DIO high-fat diet induced obese WAT white adipose tissue   
DMSO dimethyl sulfoxide    
EE  energy expenditure    
EPA eicosapentaenoic acid    
FFAs free fatty acids     
GAPDH glyceraldehyde-3-phosphate dehydrogenase  
GLP-1 Glucagon like peptide 1    
GLU glucose    
GPCR G-protein coupled receptors     
GPR40 G-protein coupled receptor 40     
HFD high-fat diet    
HOMA-
IR homeostasis model assessment of insulin resistance  
KO mice knock out mice    
KRBH Krebs-Ringer-bicarbonate HEPES buffer   
LA linoleic acid     
LCFAs Long-chain fatty acids     
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General Introduction 
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Metabolic syndrome and metabolic domino 
Metabolic syndrome (MS) is a complex disorder defined by a cluster of interconnecting 
factors which lead to the life-threatening comorbidities, and the concept of “metabolic domino” 
has been proposed to capture the flow of events and chain reactions (Itoh 2006) (Fig. 1). 
Although the genetic predisposition could influence the vulnerability and progression of 
metabolic domino for each individual, lifestyle changes including sedentary workstyle in 
combination with over calorie intake are the first dominoes to fall, which lead to obesity and 
insulin resistance, followed by postprandial hyperglycemia, hypertension, and hyperlipidemia. 
These comorbidities could be a trigger of atherosclerosis, and once diabetes occurs, the domino 
for the impairment of insulin secretion has started. Progression of the atherosclerotic process 
can lead to cardiovascular events such as ischemic heart diseases or cerebrovascular disorders. 
Preclinical and clinical data indicate that treatments which inhibit the renin angiotensin system, 
such as angiotensin receptor blockers, can suppress the onset of diabetes (Aguilar and Solomon 
2006). The inhibition of inflammation with thiazolidinedione can also block the sequence of 
events leading to cardiovascular outcomes, as was shown with pioglitazone in the Prospective 
Pioglitazone Clinical Trial in Macrovascular Events (PROactive) (Erdmann, Harding et al. 
2016). Therefore, importance of lifestyle modification and primary prevention of the MS by 
medical care should be emphasized for the improvement of QOL for the patients. 
 
Beta cell dysfunction and insulin resistance 
Islets of Langerhans, small clusters of endocrine cells, makeup ~1–2% of the total pancreatic 
mass, and each islet is composed of multiple cell types, including insulin-producing β-cells, 
glucagon-producing α-cells, and several other less abundant cell types producing somatostatin, 
pancreatic polypeptide, and ghrelin (Hornblad, Cheddad et al. 2011). The amount of insulin 
secreted in response to metabolic demand is regulated by numerous factors, with proper sensing 
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of extra cellular nutrients including glucose and free fatty acids, as well as variety of hormones 
under the healthy condition. However, once peripheral insulin resistance is established, 
hyperinsulinemia is observed as a result of increased demand for insulin and this influences β-
cells function and population markedly (Fig. 2). In addition, chronic exposure of β-cells to high 
blood glucose has detrimental effects on insulin synthesis and secretion, and affects survival 
by glucotoxicity, which in turn lead to hyperglycemia and form a vicious circle of continuous 
deterioration of β-cells dysfunction and apoptosis (Robertson, Harmon et al. 2004). Therefore, 
activation of glucose-stimulated insulin secretion may recover and prevent β-cells death via 
normalization of blood glucose for long-term benefits. 
 
Physiological function of fatty acids 
Short- and medium-chain fatty acids (SCFAs and MCFAs), along with more abundant long-
chain fatty acids (LCFAs), are natural compounds present in both animal and plant tissues that 
participate in cell metabolism (Schonfeld and Wojtczak 2016). SCFAs and MCFAs are also 
known as important food constituents, where they are mostly in the form of triglycerides in 
some plant oils and milk (Schonfeld and Wojtczak 2016). Nevertheless, bacterial fermentation 
of amylase-resistant starch and non-starch polysaccharides in the gut is probably the most 
important source of SCFAs in humans and most mammalian species (Wong, de Souza et al. 
2006) (Fig. 3). These fatty acids are not only energy sources, but also structural components of 
cell membranes (phospholipids) and second messengers (Kremmyda, Tvrzicka et al. 2011). 
Longer-chain polyunsaturated fatty acids (PUFA), including eicosapentaenoic acid (EPA), 
docosahexaenoic acid (DHA), and arachidonic acid (AA) are precursors of lipid mediators such 
as eicosanoids (prostaglandins, leukotrienes, thromboxanes), resolvins and neuroprotectins. 
The n-6 PUFA AA is the precursor of pro-inflammatory prostaglandins, leukotrienes, and 
related compounds, which have important roles in inflammation and in the regulation of 
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immunity. On the contrary, lipid mediators produced by EPA and DHA (Longer-chain n-3 
PUFA; mainly found in oily fish) are considered as inflammation-resolving, and thus, fish oil 
has been characterized as anti-inflammatory. Moreover, these fatty acids and their metabolites 
play physiologically important roles as ligands of multiple nuclear receptors affecting gene 
expressions. 
  As for the relation to pancreatic β-cells, free fatty acids (FFA) are well known to enhance 
insulin secretion in the presence of elevated plasma glucose levels (Prentki, Vischer et al. 1992, 
Yaney and Corkey 2003). Plasma concentrations of FFA are elevated in the fasted state, and 
they play a role in the enhancement of the postprandial insulin response in vivo (Stein, Esser et 
al. 1996, Dobbins, Chester et al. 1998). Thus, fatty acids are involved in multiple pathways and 
play a major role in health.  
 
Modulation of fatty acids-mediated signals for therapeutic 
potentials  
Fatty acids and their mimetics are ligands of the fatty acids binding site in proteins that 
endogenously interact. Because fatty acids and their metabolites play important roles in 
maintain the physiological functions, there are numerous examples of successful fatty acids 
mimetics with therapeutic potentials in patients (Table 1) (Proschak, Heitel et al. 2017). With 
growing knowledge of physiological importance of fatty acids through the identification of 
novel signaling cascades and deorphanization of GPCRs, pharmacological intervention to fatty 
acids-mediated signals is expected to be a useful way to tackle the MS.  
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Chapter 1: D5D activity is important for the 
development of insulin resistance and obesity  
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Abstract 
Obesity is now recognized as a state of chronic low-grade inflammation and is called as 
metabolic inflammation. Delta-5 desaturase (D5D) is an enzyme that metabolizes dihomo-γ-
linolenic acid (DGLA) to arachidonic acid (AA). Thus, D5D-inhibition increases DGLA 
(precursor to anti-inflammatory eicosanoids) while decreasing AA (precursor to pro-
inflammatory eicosanoids), and could result in synergistic improvement in the low-grade 
inflammatory state. Here, I demonstrate reduced insulin resistance and the anti-obesity effect 
of a D5D selective inhibitor (compound-326), an orally active small-molecule, in a high-fat 
diet induced obese (DIO) mouse model. In vivo D5D-inhibition was confirmed by determining 
changes in blood AA/DGLA profiles. In DIO mice, chronic inhibition of D5D lowered insulin 
resistance and caused body weight loss without significant impact on cumulative calorie intake. 
Decreased macrophage infiltration into adipose tissue was expected from mRNA analysis. 
Increased daily energy expenditure was also observed following chronic D5D-inhibition, in 
line with sustained body weight loss. These data indicate that chronic inhibition of D5D activity 
will be beneficial to prevent obese and diabetes in patients. 
 
 
Introduction 
Obesity is generally defined by an excessive fat accumulation, and is recognized as a 
pandemic nutritional disorder in both developing and developed countries (Chopra, Galbraith 
et al. 2002, Monteiro, Moura et al. 2004, Mendis, Lindholm et al. 2007, Haidar and Cosman 
2011). The cause of obesity is usually attributed to a chronic imbalance between energy intake 
and energy expenditure (EE), and is the cause of complications such as type 2 diabetes (T2DM), 
dyslipidemia, and cardiovascular disease (CVD). Although individual and genetic factors could 
influence the onset and severity, the major causative factor for obesity is the excessive intake 
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of fat and carbohydrate, partly related to the western-style-diets spreading across the world 
(Pan, Malik et al. 2012). In western-style diets, PUFA comprise up to 20% of dietary fat, and 
linoleic acid (18:2, n-6, LA) and α-linolenic acid (18:3, n-3, ALA) usually contribute more than 
95% of dietary PUFA intake, and the diets have low n-3/n-6 PUFA ratio (Simopoulos 2002, 
Simopoulos 2003, Glaser, Heinrich et al. 2010). PUFA are essential because they are not 
synthesized by the body and must be obtained through foods or supplementation (Covington 
2004). Therefore, dietary intake and food sources of PUFA could influence the whole body 
PUFA compositions (Astorg, Bertrais et al. 2008).  
Dietary LA is metabolized to dihomo-γ-linolenic acid (20:3, n-6, DGLA) by delta-6 
desaturase (D6D; Fads2) followed by delta-5 desaturase (D5D; Fads1) to arachidonic acid 
(20:4, n-6, AA), which is a substrate for the synthesis of the pro-inflammatory eicosanoids (2 
series of prostaglandins) (Fig. 4). An increase in whole desaturase activity, predicted by the 
enzyme product/enzyme substrate composition, was found in patients with essential 
hypertension (Russo, Olivieri et al. 1997), CVD (Domei, Yokoi et al. 2012), insulin resistance, 
obesity, and metabolic syndrome (Vessby 2003, Warensjo, Ohrvall et al. 2006, Inoue, Kishida 
et al. 2013). Therefore, an increased desaturase activity in combination with an n-6 rich 
environment may lead to a greater AA accumulation, thus favoring the synthesis of AA-derived 
mediators, which contribute to chronic inflammation.  
It has been reported that the D5D/D6D dual-inhibitor, CP-24879, shows beneficial effects 
against increased intracellular lipid accumulation and inflammatory injury in hepatocytes 
(Lopez-Vicario, Gonzalez-Periz et al. 2014). The anti-inflammatory action of this dual 
inhibitor could mainly be caused by D6D inhibition, which will eventually cause a decrease in 
AA production. However, D6D inhibition has a more direct impact on reducing DGLA which 
have anti-inflammatory properties; DGLA is a precursor in the synthesis of prostaglandin E1 
(PGE1) as well as 1 series of prostaglandins (Knapp, Oelz et al. 1978, Kirtland 1988, Zurier 
1991). Therefore, contrary to the D5D/D6D inhibitor, pharmacological inhibition of D5D 
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activity could decrease AA synthesis as well as increase the abundance of DGLA, and 
synergistically ameliorate metabolic abnormalities by decreasing inflammatory signals, 
especially in the situation of high LA intake (e.g., Western-style diets). 
Meanwhile, D5D is also involved in the metabolic pathway of n-3 PUFA; therefore 
inhibition of D5D may cause the decrease in de novo synthesis of eicosapentaenoic acid (20:5, 
n-3, EPA) and docosahexaenoic acid (22:6, n-3, DHA) from dietary ALA. Increasing evidence 
suggests that these n-3 PUFA exert health benefits (Swanson, Block et al. 2012, Dyall 2015); 
thus D5D-inhibition may cause some negative impacts on these beneficial effects of n-3 PUFA. 
On the other hand, recently published paper indicated that D5D knock out (KO) mice showed 
the phenotype of decreased body fat, improved glucose tolerance, lower fasting serum levels 
of insulin, cholesterol, and triglycerides compared to wild type mice without abnormal findings 
(Baugh, Pabba et al. 2015, Powell, Gay et al. 2016); therefore, D5D-inhibition could be a 
therapeutic target for metabolic disease.  
Here, I report the therapeutic potential of D5D-inhibition on obesity and insulin resistance 
using D5D selective inhibitor as a pharmacological tool. 
 
 
Materials and Methods 
Compound 
The D5D selective inhibitor, 2-(2,2,3,3,3-Pentafluoropropoxy)-3-[4-(2,2,2-trifluoroethoxy) 
phenyl]-5,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-4,6-dione, compound-326 (WO 
2010087467A1), was synthesized in Chemical Development Laboratories at Takeda 
Pharmaceutical Company Limited (Suzuki, Fujimoto et al.). Sibutramine hydrochloride 
monohydrate was purchased from Wako Pure Chemicals (Osaka, Japan). For in vivo studies, 
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compounds were suspended in 0.5 w/v% methylcellulose (MC; Wako, Osaka, Japan) solution 
and administered orally. 
 
Ethics Statement 
The care and use of the animals and the experimental protocols used in this research were 
approved by the Experimental Animal Care and Use Committee of Takeda Pharmaceutical 
Company Limited, Japan and the Guide for the Care and Use of Laboratory. During the 
experimental procedure, I monitored animals every day. Animal conditions were assessed by 
any symptoms including abnormal behavior, severe anorexia, skin ulceration, and diarrhea. No 
abnormal findings were noted, and all the mice were well-care and healthy during the 
experimental procedures. For hepatic-microsomes preparation, rats were sacrificed by 
decapitation. At the end of all the experiments, mice were sacrificed by exsanguination under 
pentobarbital anesthesia. 
 
Animals studies 
In this report, I performed 3 independent studies in DIO mice to characterize anti-obesity 
effects of the D5D-inhibition. Male C57BL/6J mice were obtained from Charles River 
Laboratories (Yokohama, Japan) or CLEA Japan (Osaka, Japan). The mice were fed a 
laboratory chow and water ad libitum and housed in a 12-h light/dark cycle. Compound or 
vehicle was administered once daily between 15: 00-19:00 by oral gavage. Body weight (BW) 
and food intake were monitored throughout the experiment. 
 
In vitro enzyme assays for desaturase activities 
Delta-9 desaturase (D9D) is a rate-limiting enzyme in the biosynthesis of monounsaturated 
fatty acids, and it was reported that D9D KO mice demonstrate resistance to diet-induced 
obesity, increased insulin sensitivity, and increased metabolic rate (Ntambi, Miyazaki et al. 
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2002). Therefore, I also confirmed that D5D inhibitor, compound-326, has no effect on D9D 
activity. Inhibitory activity of compound-326 on rat D5D, D6D, and D9D was evaluated using 
hepatic microsomes prepared from SD rats (CLEA, Japan) as described previously (Miyahisa, 
Suzuki et al. 2016). Assays were performed in a total volume of 30 μL in 96-well plates in a 
buffer containing 100 mM NaHPO4, 150 mM KCl, 10 mM NaF, 1.5 mM glutathione, 3 mM 
MgCl2, 1 mM NADH, 3 mM ATP, 0.3 mM CoA-SH, and 0.1% fatty acid free bovine serum 
albumin (BSA, Sigma, St. Louis, MO); and 0.1 μCi/well of [14C] DGLA or [14C] linoleic acids 
(ARC, St. Louis, MO) were used as substrates for measuring D5D and D6D activities, 
respectively. After pre-incubation of the test compound with rat liver microsomes (final 1.0 
mg/mL) for 5 min, the reaction was started by the addition of NADH, ATP, and the substrates, 
and the reaction mixture was incubated for another 120 min at room temperature. For D9D 
assay, [14C] stearoyl-CoA (PerkinElmer, Waltham, MA) was used in the absence of NADH, 
ATP, and CoA-SH, and D9D enzyme reaction was performed for 30 min. The reactions were 
then terminated by the addition of 0.63 N NaOH. After overnight incubation at 55C for 
saponification, the solvent extraction of fatty acids was carried out as described previously 
(Bligh and Dyer 1959). The chloroform layer was spotted on a reverse phase TLC plate, RP-
18 F254s (Merck Millipore, Darmstadt, Germany), and then developed with acetonitrile: water: 
acetic acid (95:4.5:0.5). Detection was carried out using BAS-5000 (Fujifilm, Tokyo, Japan). 
The images were digitalized using Multi Gauge ver. 2.3 (Fujifilm) and IC50 values were 
determined using the conversion ratio from the radioactive substrates (20:3n6, 18:2n6 and 18:0) 
to the products (20:4n6, 18:3n6 and 18:1n9). 
 
In vitro cell-based assay for desaturase activities 
HepG2 cells were seeded in 96-well cell culture plates at 100,000 cells/well and incubated 
overnight in DMEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 
μg/mL streptomycin in 5% CO2 at 37°C. The cells were washed twice with 200 μL of PBS and 
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incubated with the test compounds in DMEM with 0.1 % fatty acid free BSA for 30 min. Then, 
0.1 μCi/well of [14C]-labeled DGLA, linoleic acid, and stearic acid (ARC, St. Louis, MO) were 
added for each desaturase assay. After incubation for 3 h at 37°C, the cells were washed 3 times 
with 200 μL of PBS to remove [14C]-labeled substrates in the medium and 0.63 N of NaOH 
was added to saponify fatty acids. Radioactive substrates and products were extracted, 
separated, and analyzed using the method as described above.  
 
Blood and tissue fatty acids measurement 
Fatty acids were extracted from blood and tissues by adding hexane-isopropanol-butylated 
hydroxytoluene (60:40:0.01, v/v/w). Samples were vortexed for 30 min. The hexane phase was 
removed and evaporated to dryness under nitrogen stream and vacuum. Dried samples were 
dissolved in methanol and analyzed by HPLC. 
 
Anti-obesity effects of D5D-inhibition in DIO mice 
Mice were fed a high-fat diet (HFD) that has 60% kcal from fat and contains 0.09% (w/w) 
AA (D12492; Research diets, Inc., see table 2 for fatty acid profile) from 5 weeks of age, and 
they were divided into 5 groups (7 animals per group) at 11 weeks of age based on BW and 
daily food intake. In this experiment, 30 mg/kg sibutramine, a serotonin-dopamine reuptake 
inhibitor, was used as a positive control for anti-obesity effects. Mice were orally administered 
D5D selective inhibitor at doses of 0.1, 1, and 10 mg/kg, sibutramine at a dose of 30 mg/kg, or 
vehicle for 6 weeks. After 6 weeks, blood concentrations of DGLA and AA under non-fasting 
condition were evaluated as pharmacodynamics (PD) markers, and oral glucose tolerance test 
(OGTT) was performed. 
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Oral glucose tolerant test 
On the last day of the experiment, mice were given an oral glucose load (2 g/kg) after 
overnight fasting. Blood samples were collected at specified time points of 0 (pre-
glucose/fasting glucose levels), 10, 30, 60, and 120 min post glucose load for the determination 
of plasma glucose as well as insulin levels. Plasma glucose was enzymatically measured with 
auto-analyzer 7180 (Hitachi High-Technologies Corporation, Tokyo, Japan). Plasma insulin 
was measured with mouse insulin ELISA kit (Shibayagi, Gunma, Japan). The total area under 
the glucose curve was determined from time 0 to 120 min (AUC0–120 min) after glucose 
administration. Homeostasis model assessment-insulin ratio (HOMA-IR) was calculated using 
the formula: [(fasted PG: mg/dL)×(fasted insulin; μU/mL)×26/405] (Matthews, Hosker et al. 
1985).  
 
The effect of D5D-inhibition on energy expenditure in DIO mice 
To evaluate the effect on daily EE, DIO mice fed a HFD that has 41% kcal from fat and 
contains no AA (D12079B; Research diets, Inc., see table 2 for fatty acids composition) for 50 
weeks were used. At 55 weeks of age, DIO mice were divided into two weight-matched groups 
(7 animals per group) and treated with vehicle or 10 mg/kg D5D inhibitor for 11 weeks. The 
dose of D5D inhibitor, 10 mg/kg, was selected that showed clear BW reduction in the previous 
study. Indirect calorimetry test was performed on day1, 8, 15, 21, and 56 during the study. 
Daily EE was analyzed using ANCOVA with body mass as covariate (Tschop, Speakman et 
al. 2012). After the treatment period, mice were sacrificed and fat tissues were harvested to 
evaluate the weights. 
 
Indirect calorimetry test 
Energy metabolism was evaluated using an Oxymax indirect calorimetry system (Columbus 
Instruments, Columbus, OH). Mice were individually housed in the chamber with a 12-h 
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light/dark cycle. VO2 and VCO2 rates were determined with the following Oxymax system 
settings: air flow, 0.6 L/min; sample flow, 0.5 l/min; settling time, 10 min; and measuring time, 
1 min. The system was calibrated against a standard gas mixture to measure O2 consumed (VO2, 
mL/kg/h) and CO2 generated (VCO2, mL/kg/h). Metabolic rate (VO2) and respiratory exchange 
ratio (RER; ratio of VCO2/VO2) were evaluated over a 24-h period. EE was calculated as the 
product of the calorific value of oxygen (3.815+1.232×RER) and the volume of O2 consumed. 
 
Effects of D5D-inhibition on the expression of inflammation-related genes 
Mice fed a HFD that has 41% kcal from fat and contains no AA (D12079B; Research diets, 
Inc.) from 5 weeks of age were divided into 2 groups at the age of 8 weeks (8 animals per 
group), and were administered 10 mg/kg D5D inhibitor or vehicle for 6 weeks. After the 
treatment period, mice were sacrificed and epididymal and subcutaneous fats were harvested 
for mRNA analysis. Nine animals maintained on a standard chow (CE2, CLEA Japan, Osaka) 
were used as control. 
 
RNA extraction and quantitative real-time polymerase chain reaction (RT-qPCR) 
Total RNA was extracted and purified using RNeasy Mini Kit (QIAGEN, USA). First-strand 
cDNA was synthesized using High Capacity cDNA Reverse Transcription Kits (Thermo Fisher, 
USA). The mRNA levels were quantified by an ABI Prism 7900 TaqMan PCR system (Thermo 
Fisher, USA) according to the manufacturer’s instruction using TaqMan Universal PCR 
Mastermix with the primer-probe sets of TaqMan Gene Expression Assays (Thermo Fisher, 
USA) for the following genes: Ccl2 (chemokine (C-C motif) ligand 2; Mm99999056_m1), 
Cd68 (CD68 antigen; Mm03047343_m1), Adgre1 (adhesion G protein-coupled receptor E1 ; 
Mm00802529_m1), Tnf (tumor necrosis factor; Mm00443258_m1), Il6 (interleukin 6; 
Mm99999064), Lep (leptin; Mm00434759_m1), Adipoq (adiponectin; Mm00456425_m1), 
Fads2 (D5D; Mm00517221_m1), Fads1 (D6D; Mm00507605_m1), Ucp1 (uncoupling protein 
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1; Mm00494069_m1), Elovl3 (elongation of very long chain fatty acids 3; Mm00468164_m1), 
Cidea (cell death-inducing DNA fragmentation factor, alpha subunit-like effector A; 
Mm00432554_m1), Otop1 (otopetrin 1; Mm00554705_m1), and Rplp0 (ribosomal protein, 
large, P0; forward; 5'-CCCTGAAGTGCTCGACATCAC-3', reverse; 5'-
GCGCTTGTACCCATTGATGA-3', probe (VIC-5'→3'-TAMRA); 5'-
CCCTGCACTCTCGCTTTCTGGAG-3'). The Rplp0 mRNA level was used as a reference and 
relative transcript levels were calculated with the comparative Ct method (2-∆∆CT) (Applied 
Bio-systems). 
 
Statistics 
Results are expressed as mean ± SEM. Statistical analysis between two groups was assessed 
by Aspin-Welch test or Student’s t-test depending on equal or unequal variances. For these 
analyses, a p-value less than 0.05 was considered significant. The dose-dependent effect of 
D5D inhibitor vs. vehicle was evaluated by the one-tailed Williams’ test or Shirley-Williams 
test depending on equal or unequal variances and a p-value less than 0.025 was considered 
significant. 
 
 
Results 
Effect of D5Dselective inhibitor on PUFA-desaturases in vitro 
Here I used an orally bioavailable D5D selective inhibitor, compound-326, as a research tool. 
(Fig. 5) (Suzuki, Fujimoto et al.). As shown in table 3, compound-326 has a potential to inhibit 
D5D activity (IC50=72 and 22 nM for rat and human D5D, respectively); whereas, almost no 
inhibition was observed on both rat and human D6D activities. I also confirmed that compound-
326 has no effect on D9D activity. 
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Anti-obesity effects of D5D-inhibition in DIO mice 
To examine the anti-obesity potential of D5D-inhibition, I administered D5D inhibitor at 
doses of 0.1, 1, and 10 mg/kg orally to DIO mice for 6 weeks. As shown in Fig. 6A, mice 
treated with vehicle only showed increased BW during the experiment, and the sibutramine 
group showed transient and potent decrease in food intake from day 1, followed by a rebound. 
The sibutramine group showed potent BW loss for a week, but BW increased in line with 
increased food intake. On the other hand, the group treated with 10 mg/kg of D5D inhibitor 
showed gradual decrease in BW; however, lower doses were not effective. Unlike sibutramine, 
daily calorie intake was not altered significantly due to the administration of D5D inhibitor at 
all doses; although slight decrease was observed at a dose of 10 mg/kg (Fig. 6B). No abnormal 
findings such as behavioral changes, diarrhea, or steatorrhea were observed by D5D-inhibition. 
To confirm in vivo D5D-inhibition, I determined blood AA and DGLA levels after 6 weeks of 
treatment. D5D inhibitor decreased blood AA in conjunction with increased blood DGLA, in 
a dose-dependent manner (Fig. 6C); therefore, the AA to DGLA ratio decreased significantly 
(Fig. 6D). Since there was a large difference in BW loss between 1 and 10 mg/kg of D5D 
inhibitor, I analyzed statistical difference in the blood AA/DGLA profiles between these two 
doses. Although the changes were small, statistical difference was observed between the doses. 
Sibutramine treatment slightly but significantly decreased both blood AA and DGLA levels as 
well as the AA to DGLA ratio, which could be correlated to the reduction in BW. Because 
D5D is also active in the metabolic pathway of n-3 PUFA, I evaluated the effects of D5D-
inhibition on blood levels of EPA and DHA. As shown in Fig. 7, both n-3 PUFA were 
decreased by D5D inhibitor in a dose dependent manner. An OGTT was performed after 6-
week treatment, and glucose clearance was found to be improved by D5D inhibitor in a dose-
dependent manner (Fig. 8A and B), while no change was observed in the insulin levels (Fig. 
8C). In line with improved glucose clearance, HOMA-IR, an insulin resistance index, was also 
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decreased by D5D inhibitor in a dose-dependent manner (Fig. 8D). Treatment with sibutramine 
significantly improved HOMA-IR, but glucose clearance, as measured by the OGTT, was not 
improved. 
 
Effect of D5D-inhibition on daily EE in DIO mice 
As indicated above, D5D-inhibition prevented obesity and ameliorated insulin resistance 
without any appreciable decrease in calorie intake. Hence, I next confirmed the amelioration 
of obesity by D5D-inhibition using established DIO mice that had been fed a HFD for 50 weeks 
before the experiment. There was no significant difference between the groups in BW prior to 
treatment (vehicle; 50.4 ± 5.1g, 10 mg/kg D5D inhibitor; 50.9 ± 3.8g). Consistent with the 
results obtained in the HFD-fed growing DIO model, chronic D5D-inhibition caused sustained 
and significant BW reduction from day 21 until day 77 (Fig. 9A). Intriguingly, while no 
appreciable change in cumulative calorie intake was observed upon D5D-inhibition, daily 
calorie intake was slightly decreased until day 21, followed by a trend toward increase (Fig. 
9B). Mice treated with D5D inhibitor for 11 weeks showed marked decrease in the white 
adipose tissue (WAT) depot mass compared to vehicle-treated mice; mesenteric fat (p≤ 0.05), 
subcutaneous and epididymal fat (p≤ 0.01) (Fig. 9C). Since observed loss in calorie intake 
could not explain remarkable weight loss, changes in EE were monitored on days 1, 8, 15, 21, 
and 56, and daily variations are shown in Fig. 10. To evaluate the effect on EE, general linear 
model analysis was applied on each point. On days 1 and 8, no difference was observed 
between vehicle- and D5D inhibitor-treated groups when daily EE (kcal/day) was plotted 
against body mass (Fig. 11A and B). However, on day 15, daily EE lays on two separate lines 
relative to body mass (Fig. 11C), and these changes demonstrate that EE was increased by 
D5D-inhibition independent of the decreased BW (Speakman 2013). Moreover, the difference 
between these lines became more apparent on days 21 and 56, consistent with the amelioration 
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of obesity (Fig. 11D and E). D5D-inhibition lowered RER relative to vehicle-treated mice 
through the study, but the change did not reach significance (Fig. 12). 
 
Effects of D5D-inhibition on AA/DGLA ratio and gene expression in fat tissues 
To further characterize the effects of the D5D-inhibition, I evaluated changes in the 
expression of genes related to inflammation and metabolic processes in fat tissues. DIO mice 
treated with 10 mg/kg D5D inhibitor showed a resistance to obesity, and 6-week treatment 
significantly decreased BW compared to vehicle treatment (Fig. 13A and B). In addition, a 
decrease in the AA to DGLA ratio in the blood, as a consequence of decreased AA and 
increased DGLA, was confirmed in the D5D-inhibited group (Fig. 13C and D). I also evaluated 
AA and DGLA contents in the liver (Fig. 13E and F) as well as in epididymal fat tissue (Fig. 
14A and B). In HFD-fed DIO mice, the AA to DGLA ratio in the liver was significantly 
decreased compared to normal diet (ND)-fed mice; HFD-feeding increased both DGLA and 
AA, and the increase in DGLA overcame the increase in AA in the liver (Fig. 13E and F). The 
pattern of AA and DGLA changes in the liver are the same as in the blood (Fig. 13C and D). 
On the other hand, the AA to DGLA ratio in epididymal fat was significantly increased in 
HFD-fed DIO mice compared to ND-fed mice; DGLA was significantly decreased by HFD-
feeding, while AA was increased in epididymal fat tissue (Fig. 14A and B). These results 
indicate that changes in the AA to DGLA ratio, namely the D5D activity, in metabolically 
unhealthy conditions could be different in tissues, and its changes in the blood seem to reflect 
the liver conditions. However, D5D-inhibition significantly decreased the AA to DGLA ratio 
in both tissues, and the change in AA and DGLA in the blood could be a reliable PD marker to 
confirm the D5D-inhibition in tissues. I also evaluated the effect of D5D-inhibition on EPA 
and DHA levels in blood and tissues (Fig. 15); however, liver EPA level in D5D-inhinited DIO 
mice and DHA level in adipose tissue of DIO mice were not measurable due to the analytical 
detection limit. ND-fed mice showed much higher levels of EPA and DHA compared to HFD-
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fed DIO mice possibly due to the difference in the PUFA composition of the meal; CE2 diet 
contains fish-meal, while HFD do not contain any EPA or DHA (Table 2). As expected, D5D-
inhibition significantly decreased both n-3 PUFA in blood, liver, and adipose tissue. 
In epididymal fat, the expression levels of Ccl2, Cd68, and Adgre1 were significantly higher 
in HFD-fed DIO mice compared to these in ND-fed mice (Fig. 14C). And these genes were 
decreased by chronic D5D-inhibition; while significant effect of D5D-inhibition was only 
observed in Ccl2. As for Tnf and Il6 genes, up-regulation of these genes were not clearly 
observed in the HFD-fed DIO model; p value of Tnf and Il6 between HFD-fed DIO and ND-
fed mice are 1.00 and 0.46, respectively. Effects of D5D-inhibition on these inflammation-
related genes in epididymal fat were also evaluated using satellite DIO mice that had been 
treated with compound-A or vehicle for 32 days (Fig. 16). At the intermediate point, D5D-
inhibition significantly decreased gene expression levels of Ccl2, Cd68, Adgre1, and Il6 (Fig. 
16B), while no significant BW loss was observed (Fig. 16A). D5D-inhibition also decreased 
epididymal Lep and Adipoq mRNAs which were significantly increased in HFD (Fig. 14C); 
the effects did not reach statistical difference in Adipoq mRNA (p=0.08). HFD-fed DIO mice 
showed significantly lower D5D and D6D mRNA expression in epididymal fat, and D5D-
inhibition upregulated their expression. In subcutaneous fat, no induction of beige fat cell-
selective genes, including Ucp1, Cidea, Elovl3, and Otop1 were detected by D5D-inhibition 
(Fig. 14D). Lep mRNA in subcutaneous fat was decrease by D5D-inhibition, but the difference 
did not reach statistical significance (p=0.08). 
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Discussion 
Considering the physiological importance of PUFA, D5D and D6D activities are likely 
regulating a number of metabolic and inflammatory pathways. In addition, the use of product-
to-precursor ratio as surrogate to estimate desaturase activity is well established, and this 
method has been used in epidemiological studies (Vessby, Gustafsson et al. 2002). In such 
studies, D6D has received much more attention compared to D5D with respect to metabolic 
disorders, because data demonstrated strong positive correlations between increased D6D 
activity and insulin resistance, BMI, and T2DM, while D5D activities showed negative 
correlation (Warensjo, Ohrvall et al. 2006, Steffen, Vessby et al. 2008, Warensjo, Rosell et al. 
2009, Park, Hasegawa et al. 2010, Kroger, Zietemann et al. 2011, Saito, Okada et al. 2013). 
Additionally, metabolic benefits of D6D-inhibition were also predicted from the results that 
D6D KO mice exhibited resistance against HFD-induced obesity (Stoffel, Hammels et al. 
2014).  
Regarding D5D, Powell et al. recently reported that D5D KO mice showed lean phenotype 
with improved glycemic control and decreased development of atheromatous plaque under 
HFD-feeding (Powell, Gay et al. 2016). Hence, although there is no clear human evidence 
available to support the metabolic benefits of D5D-inhibition, the concept is similar to D6D-
inhibition; it will block the supply of AA, which is required for the production of pro-
inflammatory eicosanoids. In addition, D5D-inhibition increases the abundance of DGLA, 
which is a known precursor for anti-inflammatory eicosanoids. Thus, pharmacological 
inhibition of D5D activity may synergistically ameliorate metabolic abnormalities by 
decreasing inflammatory signals due to the decrease in AA/DGLA ratio. 
In the first study, I found that 6-week D5D-inhibition prevented HFD-induced obesity with 
a slight decrease in daily calorie intake; although it was not enough to explain the remarkable 
change in BW. Here, I used sibutramine, which produces anorexigenic effects by 
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norepinephrine, serotonin, and dopamine reuptake inhibition, as a positive control for anti-
obesity effect. Intriguingly, although both sibutramine and D5D inhibitor showed potent loss 
in BW, D5D inhibitor did not decrease food intake as sibutramine. 
As indicated above, fatty acid product-to-precursor ratio in the blood has been widely used 
to estimate PUFA desaturase activity (Vessby, Gustafsson et al. 2002); hence, I used changes 
in the blood AA to DGLA ratio to estimate the inhibition of D5D activity by the test compound. 
As expected from in vitro studies, blood samples from mice with D5D-inhibition showed 
decreased AA and increased DGLA in a dose-dependent manner, and these results indicate that 
compound-326 has a potential to inhibit D5D activity in vivo. Although a significant change in 
BW could only be observed at a higher dose (10 mg/kg) having a high impact on blood AA 
and DGLA levels, improvement in glucose tolerability and insulin sensitivity were observed 
from dose of 1 mg/kg without a significant decrease in BW. These results suggest that near 
complete inhibition of D5D may be required for loss of BW, while partial inhibition may be 
enough to improve insulin sensitivity. 
I also evaluated anti-obesity effect of D5D inhibition in established DIO mice, and chronic 
treatment with 10 mg/kg D5D inhibitor reduced BW, but had a lower effect on calorie intake. 
While short-term D5D inhibition did not increase EE, chronic administration increased EE in 
line with BW reduction. These results suggest that increased EE by D5D inhibition may require 
modified cellular AA and DGLA profiles, which would require a longer period. 
Although D5D inhibition could exert an influence on AA and DGLA profiles in the whole 
body, here I focused on the anti-inflammatory response in adipose tissue, because inflammation 
originating from excessive amount of visceral fat is considered as one of the main driving 
forces in the development of metabolic abnormality in obese individuals. CCL2, a potent 
chemotactic factor for monocyte, is produced predominantly by macrophages and its 
abundance in adipose tissue is increased in obese mice (Sartipy and Loskutoff 2003). In the 
adipose tissue, increased CCL2 signaling through its receptor, CCR2, links obesity and insulin 
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resistance through the induction of an inflammatory response (Kanda, Tateya et al. 2006). I 
found that macrophage-related genes, exemplified by Ccl2, Adgre1, and Cd68 were 
upregulated in epididymal fat of HFD-fed DIO mice compared to normal mice, and chronic 
D5D-inhibition decreased the expression of these genes, thereby improvement on 
inflammation could be expected in the adipose tissue while further studies are necessary in 
order to clarify the association. I also confirmed a decrease in the AA to DGLA ratio in 
epididymal fat due to D5D-inhibition, and these changes could contribute toward improved 
insulin sensitivity by suppressing systemic inflammation in the adipose tissue. It is reported 
that insulin stimulates D5D and D6D gene expression in hepatocytes via a cAMP dependent 
mechanism (Rimoldi, Finarelli et al. 2001). Hence, increased D5D and D6D mRNA expression 
observed in fat tissue would be caused by improved insulin sensitivity. Leptin is a hormone 
synthesized and released by WAT, and plays an important role in maintaining energy balance 
and regulation of BW (Zhang, Proenca et al. 1994). In my results, chronic D5D-inhibition led 
to a marked decrease in leptin mRNA expression in epididymal fat, which could largely be 
attributed to body fat loss and improved leptin resistance. 
Body fat accumulation, and consequently increase in BW, fluctuates in accordance with the 
difference between energy intake and EE over time. Here, I examined energy balance in detail 
and found that chronic D5D-inhibition significantly increased daily EE. The increase in EE 
with a concomitant slight decrease in energy intake resulted in a severe negative energy balance 
responsible for the observed fat and weight loss. Some interventions, which modulate 
metabolic fluxes in adipocytes, result in a general decrease in the accumulation of body fat. 
Pharmacological stimulation of PPARα (Hondares, Rosell et al. 2011) or leptin treatment 
(Wang, Lee et al. 1999) increase UCP1 positive cells in WAT, which mediate thermogenesis 
and mitochondrial uncoupling, and they are known as beige fat cells. It was reported that 
dietary AA has a negative influence on the production of beige fat cells upon β3-adrenergic 
receptor stimulation (Pisani, Ghandour et al. 2014). Therefore, I evaluated the expression levels 
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of beige fat cell-selective genes such as Ucp1, Elovl3, Cidea, and Otop1 in subcutaneous fat, 
but no change was observed upon D5D-inhibition. 
AA is also the substrate for the synthesis of anandamide and other endocannabinoids. It is 
well known that rimonabant, a selective inverse agonist of cannabinoid receptor 1 (CB1), has 
shown to cause weight loss due to decreased food intake and increased EE (Zhang, Gamo et al. 
2012). Studies in rodents indicated that chronic rimonabant treatment upregulated UCP1 
expression both in interscapular brown adipose tissue (BAT) and WAT adipocytes via 
increased sympathetic activity (Verty, Allen et al. 2009, Perwitz, Wenzel et al. 2010). Although 
D5D-inhibition showed much less impact on food reduction and UCP1 induction in WAT, 
decreased cannabinoid signaling in BAT may exert increased EE through a similar mechanism 
as chronic rimonabant treatment. Thus, while increased EE by chronic D5D-inhibition may 
contribute to its anti-obesity effect, further studies are required to delineate the mechanism of 
the increase in EE. 
Contrary to these beneficial effects of D5D-inhibition, there are two major concerns for 
future development. One of the considerable concerns is the fact that D5D-inhibition also 
affects the n-3 PUFA desaturation pathway. Here, I observed decreased blood and tissue levels 
of DHA and EPA by D5D-inhibition in mice. Although any abnormal findings were not 
observed in the mice with pharmacological D5D-inhibition even in the absence of EPA and 
DHA intake (Table 2), this on-target effect may have some negative impact from the 
therapeutic point of view due to the increasing number of the positive evidence of n-3 PUFA 
on human health (Swanson, Block et al. 2012, Dyall 2015). Another possible concern is the 
risk of varying efficacy under the different PUFA composition in foods. In the current 
experiments, I used the HFD that contains high amount of LA and low or no amount of AA 
(Table 2), and exemplified the possibility that the D5D-inhibition may exert both anti-
inflammatory and anti-obesity effects when taking the high-LA diet, such as western-style diets. 
On the other hand, dietary intake of AA or other PUFA may attenuate the therapeutic efficacy 
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of D5D-inhibition in line with the increase in blood and tissue AA/DGLA ratio. Therefore, 
more experiments are necessary to elucidate the mechanism of action of D5D-inhibition on 
anti-obesity and anti-inflammatory potentials, and clear mitigation plans for potential concerns 
and problems are required. 
In conclusion, I showed the availability of the blood AA to DGLA ratio as a useful PD 
marker for D5D-inhibition. I also confirmed a sub-chronic effect of D5D-inhibition on insulin 
sensitivity and body fat loss with increased EE. Although further characterization is required 
to understand the physiological and pathophysiological impact on PUFA-desaturase pathways, 
D5D selective inhibition will be a new strategy for the improvement of obese and diabetic 
patients.   
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Chapter 2: GPR40 mediated signal contributes 
to pancreatic hormone secretion   
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Abstract 
G protein-coupled receptor 40 (GPR40)/free fatty acid 1 (FFA1) is a G protein-coupled 
receptor involved in free fatty acid-induced insulin secretion. To analyze the effect of GPR40-
selective activation on insulin and glucagon secretion, I performed hormone secretion assays 
and measured intracellular Ca2+ concentration ([Ca2+]i) using TAK-875, a synthetic GPR40 
selective agonist, in both human and rat islets. Insulin and glucagon secretion were measured 
in static and dynamic conditions by using groups of isolated rat and human pancreatic islets. 
[Ca2+]i was recorded by using confocal microscopy. GPR40 expression was measured by 
quantitative polymerase chain reaction. In both human and rat islets, stimulation of GPR40 
signal enhanced glucose-stimulated insulin secretion in a glucose-dependent manner. The 
stimulatory effect by GPR40 agonist was similar to that produced by glucagon-like peptide-1 
and correlated with the elevation of β-cell [Ca2+]i. Activation of GPR40 signal was without 
effect on glucagon secretion at both 1 and 16 mM glucose in human islets. These data indicate 
that GPR40 influences mainly insulin secretion in a glucose-dependent manner. The β-cell-
specific action of GPR40 agonist in human islets may represent a therapeutically useful feature 
that allows plasma glucose control without compromising counter-regulation of glucagon 
secretion, thus minimizing the risk of hypoglycemia. 
 
 
Introduction 
Insulin and glucagon have opposite effects on the regulation of plasma glucose levels. 
Insulin, which is secreted from pancreatic β-cells in response to increased plasma glucose, 
decreases hepatic glucose production and increases glucose uptake in multiple tissues (Frayn 
2003). Impaired insulin secretion is a major cause of the onset and development of type 2 
diabetes, and drugs that enhance insulin secretion, such as sulfonylureas and glinides, are 
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commonly used for its treatment (Marchetti, Dotta et al. 2008). On the other hand, glucagon 
secretion from pancreatic α-cells is suppressed in response to elevated blood glucose levels, 
whereas reduced blood glucose enhances glucagon release. Glucagon is the principal hormone 
stimulating hepatic glucose production. Glucagon secretion is inappropriately high at elevated 
plasma glucose levels in diabetic patients, which contributes significantly to the hyperglycemia 
that is a hallmark of the disease (Shah, Basu et al. 1999). Thus, impaired regulation of both 
insulin and glucagon secretion plays a prominent role in the etiology of diabetes. 
The mechanism of insulin secretion from β-cells is well understood: glucose metabolism 
increases the intracellular ATP/ADP ratio, which in turn closes ATP-sensitive potassium 
channels (KATP channels) and activates voltage-gated calcium channels (Ca
2+ channels) (Fig. 
17). The resultant stimulation of Ca2+ influx and associated elevation of [Ca2+]i triggers insulin 
exocytosis (MacDonald, Joseph et al. 2005). The mechanisms regulating glucagon secretion 
from α-cells remain debated. It has been suggested that glucose can suppress glucagon 
secretion through a direct effect on α-cell activity (Gromada, Ma et al. 2004), but there is also 
evidence that glucagon secretion is under paracrine and neuronal control (Miki, Liss et al. 2001, 
Gromada, Franklin et al. 2007). Although the precise mechanism by which glucose regulates 
glucagon secretion is currently unclear, there is consensus that glucagon secretion from α-cells 
depends on an elevated [Ca2+]i (Nadal, Quesada et al. 1999). Spontaneous [Ca
2+]i oscillations 
are seen in α-cells exposed to low glucose concentrations (i.e., conditions associated with the 
stimulation of glucagon release). Glucose-induced suppression of glucagon secretion has been 
proposed to involve a reduction of [Ca2+]i (Berts, Gylfe et al. 1995, Quesada, Nadal et al. 1999, 
Barg, Galvanovskis et al. 2000, Gopel, Kanno et al. 2000), but there are conflicting data (Le 
Marchand and Piston 2010). 
Free fatty acids (FFA) act as a primary energy source in the body, but they also act as 
systemic and intracellular signaling modulators. Acute exposure to FFA leads to the stimulation 
of insulin secretion (Olofsson, Salehi et al. 2004), whereas prolonged exposure leads to the 
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inhibition of glucose-stimulated insulin secretion (Olofsson, Collins et al. 2007, Hoppa, Collins 
et al. 2009). FFA also influence glucagon secretion from isolated mouse islets (Olofsson, Salehi 
et al. 2004). The acute effects involve stimulation of glucagon secretion at both high and low 
glucose concentrations, whereas long-term exposure is associated with stimulated release at 
low glucose levels and loss of glucose-induced suppression (Collins, Salehi et al. 2008). These 
effects of FFA on insulin and glucagon secretion require transport of the FFA across the plasma 
membrane and metabolism by long-chain FA-CoA (Prentki, Joly et al. 2002). However, the 
finding that FFA also act as a ligand of G protein-coupled receptor 40 (GPR40) suggests an 
alternative or additional regulatory mechanism (Morgan and Dhayal 2009). GPR40 was found 
as an orphan G protein-coupled receptor, and it couples mainly with Gαq protein (Itoh, 
Kawamata et al. 2003, Fujiwara, Maekawa et al. 2005, Tomita, Masuzaki et al. 2006) (Fig. 17). 
The activation of GPR40 by FFA increases [Ca2+]i by a Gαq-mediated pathway and thus 
stimulates insulin secretion in a glucose-dependent manner (Fujiwara, Maekawa et al. 2005). 
In rodents, GPR40 is highly expressed in pancreatic β-cells, but the expression within α-cells 
remains controversial (Flodgren, Olde et al. 2007, Hirasawa, Itsubo et al. 2008). GPR40 is 
highly expressed in human pancreatic islets (Tomita, Masuzaki et al. 2006), but there is little 
information about the cellular distribution of GPR40 within an islet. 
TAK-875 is a potent and highly selective agonist for GPR40 and improves glucose tolerance 
via stimulation of glucose-induced insulin secretion in type 2 diabetic rats (Negoro, Sasaki et 
al. 2010, Tsujihata, Ito et al. 2011). The possibility that GPR40 activation may possesse a 
glucose-dependent mode of action, thus minimizing the risk of hypoglycemia, makes it a 
promising candidate for future diabetes therapy. Here, I have compared the effects of GPR40 
activation on insulin and glucagon secretion in isolated human and rat pancreatic islets. My 
data suggest that whereas GPR40 signal influences insulin and glucagon secretion in rat islets, 
its effect is restricted to insulin secretion in human islets. 
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Materials and Methods 
Cell culture 
Rat islets were isolated from pancreas of 180- 250-g female Sprague-Dawley rats by 
digestion with collagenase type-IV (Sigma) solution dissolved in HBSS (Sigma) at a final 
concentration of 1.9 U/mL. Islets were handpicked under a stereomicroscope and cultured 
overnight in RPMI1640 medium (GIBCO) containing 10% FCS, penicillin (100 U/mL), 
streptomycin (100 μg/mL), and 5 mM glucose at 37°C in 95% air with 5% CO2. Human 
pancreases were obtained with ethical approval and clinical consent from non-diabetic donors. 
Islets were isolated by collagenase digestion in the Diabetes Research and Wellness Foundation 
Human Islet Isolation Facility (University of Oxford) using established methods (Ricordi, Lacy 
et al. 1988). Human islets were cultured in H-cell medium (SBMI 06, H-cell technology Inc., 
USA) at 37°C in 95% air with 5% CO2. 
 
Chemicals 
TAK-875 (Negoro, Sasaki et al. 2010) was synthesized in the Chemical Development 
Laboratories at Takeda Pharmaceutical Company Limited, and dissolved in DMSO. Glucagon-
like peptide-1 (7-37) amide (GLP-1) was purchased from Bachem (Weil am Rhein, Germany). 
 
Static incubation assay 
Krebs-Ringer bicarbonate HEPES buffer (KRBH) containing 130 mM NaCl, 5 mM KCl, 1 
mM MgSO4, 1 mM NaH2PO4, 27 mM NaHCO3, 25 mM HEPES and 2.8 mM CaCl2 
supplemented with 0.2% FFA-free BSA (Sigma) was used as the assay buffer. After overnight 
culture, batches of 8-10 islets were washed twice with RPMI 1640 medium containing 10% 
FCS, penicillin (100 U/mL) and streptomycin (100 μg/mL) in assay tubes, and pre-incubated 
for 1 h with assay buffer containing 1 mM glucose at 37°C. The extracellular buffer was then 
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substituted with assay buffer (0.3 mL) containing 1 or 16 mM glucose with 0.1% DMSO 
(control) or test substances (dissolved in an equal amount of DMSO). After 1 h incubation at 
37°C, aliquots for subsequent measurements of insulin and glucagon were taken. Insulin was 
measured with a rat insulin RIA kit (Linco, USA) or human insulin-specific RIA kit (Linco, 
USA). Secreted glucagon was measured with a glucagon RIA kit (Linco, USA). Islet insulin 
and glucagon contents were measured after acid ethanol (0.15 mL; 0.18 mM HCl, in 70% 
ethanol) extraction of islet homogenates.  
 
Islet perifusion analysis  
Time-dependent change in insulin release from isolated islets was assessed using a multi-
chamber perifusion system maintained at 37°C. Batches of 160 islets were loaded into 
Millipore chambers (Swinnex 13; 1 μm filter) and pre-perifused (0.5 ml/min) for 30 min with 
KRBH at initial glucose concentration (5 mM) with 0.1% DMSO (control) or TAK-875 (3 µM). 
The perifusion buffers were then switched to the buffers containing different concentrations of 
glucose with 0.1% DMSO or TAK-875, and perifusate samples were collected every 1-2 min. 
Secreted insulin and islet insulin content (extracted by acid ethanol) were determined as 
described above. 
 
Intracellular Ca2+ measurements 
Intact rat or human islets were loaded with 2 μM fluo-4-AM (Molecular Probes) in RPMI 
1640 (GIBCO) medium containing FFA-free BSA (0.01% for rat islets, and 0.2% for human 
islets), penicillin (100 U/mL), streptomycin (100 μg/mL) and 5 mM glucose for at least 2 h at 
room temperature before the imaging experiments commenced. Islets were immobilized with 
a wide-bore holding pipette in a continuously superfused and temperature-controlled (37°C) 
bath mounted on the stage of an Axioskop 2 FS-mot microscope (Carl Zeiss). KRBH 
supplemented with 0.01% FFA-free BSA was used as a perifusion buffer. Images were 
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collected using an LSM 510 system (Carl Zeiss) at 1.48-second intervals. Excitation was with 
a 488 nm argon laser, and emitted fluorescence was collected through 500-550 nm band-pass 
filters for the fluo-4 signal. Prior to experimental recordings, islets were perifused for 10 min 
with the perifusion buffer with 1 mM glucose and 0.1% DMSO. This was followed by 
perifusion with a buffer containing 16 mM glucose and 0.1% DMSO (v/v) and finally by 16 
mM glucose plus 3 μM TAK-875 (in 0.1% DMSO). The [Ca2+]i response was determined by 
baseline subtraction and plotted as change in fluorescence intensity (%ΔF/F), expressed as 
follows: %Δ/F = (F(t)-Fmin)/(Fmax-Fmin)×100. Single β- and α-cells within islets were identified 
by their reciprocal regulation by glucose as previously described (Berts, Gylfe et al. 1995, 
Quesada, Nadal et al. 1999, Barg, Galvanovskis et al. 2000, Gopel, Kanno et al. 2000). Briefly, 
when glucose concentration is switched from low (1 mM) to high (16 mM), insulin-secreting 
β-cells show transient spikes or sustained increase of [Ca2+]i. On the other hand, glucagon-
secreting α-cells present [Ca2+]i oscillations in response to low glucose tend to become silent 
at high glucose (MacDonald, De Marinis et al. 2007). To evaluate the effects of GPR40 
activation, the area under the [Ca2+]i-curve for each given treatment period was calculated and 
reported as arbitrary units (AU). 
 
Quantification of mRNA expression of GPR40 and other receptor genes 
Four batches of human islets were used in these experiments. Total RNA was extracted from 
50-100 human islets and purified using a QIA shredder and QIAGEN RNeasy Mini Kit 
(QIAGEN, Germany). Genome DNA was digested using RNase-free DNase (QIAGEN). First-
strand cDNA was synthesized by random hexamer-primed reverse transcription using a 
TaqMan Reverse Transcription Reagents kit (Applied Biosystems, USA). The mRNA levels 
were quantified by an ABI Prism 7900 TaqMan PCR system (Applied Biosystems) according 
to manufacturer’s instruction using TaqMan Universal PCR Mastermix (Applied Biosystems). 
Copy numbers of the target genes were determined by the standard curve method using 
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synthesized and PAGE-purified oligo DNA fragments (Sigma Genesis, UK) containing the 
PCR amplicon regions. The mRNA expression in each gene was normalized to that of GAPDH. 
The specific primers and probes were synthesized (Applied Biosystems) according to published 
sequences (Tomita, Masuzaki et al. 2006). Primer sequences are given in table 4. 
 
Statistical analysis 
  Results were expressed as mean ± SEM. Statistical analysis between two groups was 
assessed by Student’s t-test or the Aspin-Welch test as indicated. A p-value of ≤ 0.05 was 
considered statistically significant. The dose-dependent effects of TAK-875 vs. control on 
hormone secretion assays were evaluated by the one-tailed Williams’ test and a p-value of ≤ 
0.025 was considered significant. 
 
 
Results 
GPR40 signal on insulin and glucagon secretion in isolated rat islets 
 In rat islets, high glucose (16 mM) increased insulin secretion 3.3-fold compared to low 
glucose (1 mM). Addition of TAK-875 (0.1-1 μM) or GLP-1 (0.01 μM) potentiated the 
stimulatory effect of high glucose but both compounds were ineffective at the low glucose 
concentration (Fig. 18A). As expected, increasing glucose from 1 to 16 mM resulted in reduced 
glucagon secretion. Consistent with what is observed in mouse islets (De Marinis, Salehi et al. 
2010), GLP-1 inhibited glucagon secretion at low glucose and 0.1 µM TAK-875 was equally 
inhibitory. A 10-fold higher concentration of TAK-875 did not inhibit glucagon secretion in 
excess of the inhibition produced by 0.1 μM. Neither compound enhanced the inhibitory effect 
of high glucose (Fig. 18B).  
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GPR40 signal on 1st and 2nd phases of insulin secretion at high glucose in perifused 
rat islets 
 To analyze the effect of GPR40 activation on 1st and 2nd phase insulin secretion, dynamic 
measurements of insulin secretion were obtained by perifusion of isolated rat islets. As shown 
in Fig. 19A, TAK-875 (3 μM) had no stimulatory effect on insulin secretion at 5 or 1 mM 
glucose and, if anything, inhibited secretion. However, a strong stimulation was observed at 16 
mM glucose. The stimulatory effect was particularly pronounced for 2nd phase insulin 
secretion; the area under the curve (AUC) measured during 1st (62-69 min) and 2nd phase (70-
82 min) increased 2.3- and 3.9-fold, respectively (Fig. 19B). The stimulatory effect of 16 mM 
glucose in both the absence and presence of GPR40 agonist was promptly reversed upon 
reduction of glucose to 5 mM. 
 
GPR40 signal on [Ca2+]i in individual cells within intact rat islets 
I next examined the effects of TAK-875 (3 μM) on [Ca2+]i responses in individual β- and α-
cells within isolated intact rat islets (Fig. 20A). When glucose concentration was switched from 
low (1 mM) to high (16 mM), β-cells responded with either transient spikes or a sustained 
increase in [Ca2+]i. Addition of GPR40 agonist at high glucose concentration resulted in a 
further elevation of [Ca2+]i in β-cells (Fig. 20B; Rβ1, 2). In α-cells, identified by the generation 
of [Ca2+]i oscillations at 1 mM glucose, increasing glucose to 16 mM reduced the amplitude of, 
but did not suppress, these [Ca2+]i oscillations. These effects of glucose were not changed by 
the inclusion of GPR40 agonist in the superfusion medium (Fig. 20B; Rα1, 2). The effects of 
glucose and GPR40 agonist on β- and α-cell [Ca2+]i are indicated in Fig. 20C and D. 
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Comparison of gene expression levels of GPR40, GLP-1R and SUR1 in human 
islets 
GPR40 is highly expressed in rodent islets but there is little information about the expression 
levels in human islets. Therefore, I first quantified mRNA expression of GPR40 in human islets 
from four non-diabetic organ donors. Donor characteristics are given in table 5. The expression 
of GPR40 in human islets was comparable to that of the GLP-1 receptor (GLP-1R) (Fig. 21). 
Expression of GPR40 was also compared to the KATP-channel subunit SUR1. Again, GPR40 
expression was found to be at least as high as that of the reference gene. Thus, GPR40 is 
expressed in human islets at levels comparable to or higher than those of two other genes that 
encode proteins with key roles in islet/β-cell function. This prompted me to investigate the 
effects of GPR40 agonist on insulin and glucagon secretion from human islets. 
 
GPR40 signal on insulin and glucagon secretion in isolated human islets 
The effects of TAK-875 at 1 or 16 mM glucose on insulin and glucagon secretion in human 
islets were measured in static incubations. A total of 4 donors was used for the experiments 
reported here (Table 5). The responses observed with islets from individual donors are 
summarized in table 6. Fig. 22 presents the mean responses for all four donors. Since the 
amount of secreted insulin and glucagon varied among these four batches, they were expressed 
as % of each control (low glucose alone). It is evident that 16 mM glucose stimulates insulin 
secretion >3-fold and that this effect is enhanced by 3 µM TAK-875; lower concentrations 
tended to increase insulin secretion but this effect did not reach statistical significance. The 
effect of GPR40 activation was comparable to the stimulation observed in response to GLP-1; 
no stimulation by GPR40 activation was observed at 1 mM glucose. Increasing glucose to 16 
mM glucose inhibited glucagon secretion. GPR40 activation was without effect on glucagon 
secretion at any of the concentrations tested at 1 or 16 mM glucose. GLP-1 did not exert an 
additive inhibitory effect when applied in the presence of 16 mM glucose (Fig. 22B). 
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GPR40 signal on [Ca2+]i in individual cells within intact human islets 
The effects of TAK-875 (3 μM) on [Ca2+]i responses in individual β- and α-cells were also 
investigated in intact human islets from three non-diabetic donors (Fig. 23A). The donor 
characteristics are given in table 5. As observed in rat islets, human β-cells responded with 
elevation of [Ca2+]i when glucose concentration was switched from 1 to 16 mM glucose, and 
the addition of GPR40 agonist to islets already exposed to high glucose resulted in a further 
elevation in many of the β-cells (Fig. 23B; Hβ 1-2). Fig. 23C summarizes the effects of 16 mM 
glucose in the absence and presence of GPR40 agonist. As in rat islets, I observed cells that 
were spontaneously active at 1 mM glucose and that are therefore likely to be α-cells. However, 
a spontaneous time-dependent decrease in the amplitude of these oscillations made it difficult 
to evaluate the effects of glucose and GPR40 agonist, and I therefore refrained from 
quantitative analysis of these data from α-cells. 
 
 
Discussion 
Because activation of GPR40 signaling evoked by medium- or long-chain FFA enhances 
glucose-stimulated insulin secretion (Itoh, Kawamata et al. 2003, Fujiwara, Maekawa et al. 
2005), potent and specific GPR40 agonists may be useful for the treatment of T2DM Although 
published reports show that small-molecule agonists for GPR40 stimulate glucose-dependent 
insulin secretion in both in vitro and in vivo rodent models (Briscoe, Peat et al. 2006, Bharate, 
Nemmani et al. 2009), there is as yet no evidence that GPR40 agonists are effective in human 
islets. In addition, the effects of selective GPR40 agonists on glucagon secretion have not been 
elucidated. Here, I have examined the effects of GPR40 agonist, TAK-875, on insulin and 
glucagon secretion and [Ca2+]i in rat and human pancreatic islets. The significance of such 
comparative studies is highlighted by electrophysiological studies demonstrating major 
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differences in the ion channel complements expressed in human and rodent islet cells (Braun, 
Ramracheya et al. 2008, Ramracheya, Ward et al. 2010). It is unlikely that these differences 
will be restricted to ion channels and those are already documented. 
I found that GPR40 is expressed at levels comparable with those for GLP-1R and SUR1 in 
human islets. Similar results have been reported in rat islets (Itoh, Kawamata et al. 2003). GLP-
1R and SUR1 play important roles in β-cell function, and they constitute to the molecular 
targets of two groups of insulinotropic drugs: GLP-1 analogs and sulfonylureas. I showed that 
GPR40 agonist augments glucose-stimulated insulin secretion in a way reminiscent of the 
action of GLP-1 in both rat and human islets. The dynamic measurements of insulin secretion 
reveal that although GPR40 agonist enhances both first- and second-phase insulin secretion in 
a strictly glucose-dependent fashion, the stimulatory effect is particularly pronounced for 
second-phase release. 
The insulin-releasing capacity of GPR40 agonist correlated with elevation of [Ca2+]i. It has 
been proposed that GPR40, via inositol trisphosphate production, mobilizes Ca2+ from the 
endoplasmic reticulum (Fujiwara, Maekawa et al. 2005). Alternatively, GPR40 signal may act 
by enhancing entry of extracellular Ca2+ via the voltage-gated Ca2+ channels. This could result 
from a direct effect on the voltage-gated Ca2+ channels or an indirect effect caused by closure 
of the KATP channels (Feng, Luo et al. 2006). The exact mechanism of the glucose-dependent 
insulinotropic action of GPR40 signal remains to be elucidated and is beyond the scope of the 
current investigation, the primary objective of which was to compare the action of GPR40 
stimulation on hormone secretion from human and rat islets. 
The human islet preps showed some heterogeneity in insulin secretion, and one batch (donor 
7) was unresponsive to 1 μM TAK-875 (Table 6), but it should be noted that the same islets 
responded to the agonist with an elevation of [Ca2+]i (Fig. 24). Studies on islets from a greater 
number of donors are therefore needed to determine whether there is a true heterogeneity in 
responsiveness to GPR40 activation. 
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I also showed that GPR40 activation tends to inhibit rather than stimulate glucagon secretion 
induced by low glucose in rat islets, but without effect on glucagon secretion from human islets. 
The presence of GPR40 in rodent α-cells is debated (Flodgren, Olde et al. 2007, Hirasawa, 
Itsubo et al. 2008). However, GPR40 expression in human islets seems dominant in insulin-
positive cells (Itoh, Kawamata et al. 2003, Tomita, Masuzaki et al. 2006). Thus, one 
explanation for the lack of glucagonostatic action in human islets might reflect the low GPR40 
expression in human α-cells. Another explanation is that GPR40 activation might affect 
paracrine factors, such as somatostatin secretion, and the contribution might be different 
between species. 
It was reported that linoleic acid, one of the endogenous agonists for GPR40, stimulates 
glucagon secretion in rodent islets (Flodgren, Olde et al. 2007, Wang, Zhao et al. 2011). By 
contrast, my results indicate that GPR40 agonist is without stimulatory effect on glucagon 
secretion in both rat and human islets and if anything tends to inhibit glucagon secretion in rat 
islets exposed to low glucose. TAK-875 is >400-fold more potent at activating human GPR40 
than oleic acid, which shows agonist activity almost similar to that of linoleic acid (Tsujihata, 
Ito et al. 2011). These results clearly suggest that, unlike physiological agonists, the activation 
of GPR40 by a selective synthesized agonist has no potential to enhance glucagon secretion. 
With regard to the interaction of TAK-875 with the endogenous ligands (FFA), it is of 
interest that TAK-875 potently stimulates insulin secretion during oral glucose tolerance tests 
in diabetic rats fasted overnight, in which plasma FFA levels are elevated because of the 
stimulation of lipolysis (Tsujihata, Ito et al. 2011). These data suggest that TAK-875 may show 
positive cooperativity with endogenous ligands. The role of GPR40 in FFA-regulated glucagon 
secretion merits further studies, and it deserves pointing out that FFA may influence glucagon 
secretion by mechanisms that do not involve GRP40 (Olofsson, Salehi et al. 2004). 
As for the glucagonostatic action of GPR40 agonist at 1 mM glucose in rat islets, a lower 
dose (0.1 μM) is paradoxically more potent than a higher dose (1 μM). The underlying 
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mechanisms are unclear but it is worth remembering that this “anomaly” is shared with other 
modulators of glucagon secretion. Thus, glucose, adrenaline, and forskolin inhibit glucagon 
secretion at a low concentration, whereas higher concentrations are less inhibitory (glucose; 
(Vieira, Salehi et al. 2007)) or even stimulatory (adrenaline and forskolin; (De Marinis, Salehi 
et al. 2010)). 
My data suggest that the effects of GPR40 agonist on glucagon secretion differ between rat 
and human islets. This underscores the importance of confirming in human islets observations 
made in rodent islets. The clinical relevance of the lack of effect of GPR40 agonist on glucagon 
secretion remains to be determined. Diabetes is associated with hypersecretion of glucagon at 
elevated plasma glucose levels. Pharmacological treatment of hyperglycemia and 
hypoinsulinemia is complicated by an impaired counter-regulation by glucagon during 
hypoglycemia. From this perspective, it may be argued that the selective action of GPR40 
activation on insulin secretion at high glucose may be clinically beneficial. 
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General Discussion 
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Metabolic syndrome (MS) is a complex disorder defined by a cluster of interconnecting 
factors which lead to life-threatening comorbidities, and a concept of metabolic domino has 
been proposed to capture the flow of events and chain reactions. To clarify the contribution of 
fatty acids mediated signals on the onset of MS, I examined the physiological importance of 
delta-5-desaturase (D5D) mediated metabolism on the obesity and insulin resistance (Chapter 
1), and G-protein coupled receptor 40 (GPR40) on the glucose-stimulated insulin secretion 
from the pancreatic islets (Chapter 2).  
In the first chapter, I found the evidence that sub-chronic pharmacological inhibition of D5D 
improves insulin sensitivity and body fat loss with increased EE in DIO mice. My results were 
consistent with the fact that D5D KO mice shows beneficial metabolic phenotype for obesity, 
diabetes, and atherosclerotic cardiovascular disease (Powell, Gay et al. 2016). Although further 
characterization is required, my data suggest that induction of EE and anti-inflammatory action 
are potential mechanisms of D5D inhibition for obesity and insulin resistance.  
Contrary to the beneficial effects of D5D inhibition, I also discussed 2 potential concerns 
regarding pharmacological inhibition. 1) Since D5D also contributes to the n-3 PUFA 
desaturation pathway, decreased blood and tissue levels of DHA and EPA were observed in 
D5D inhibitor-treated mice. This on-target effect may have negative impacts on the therapeutic 
point of view based on the beneficial evidence of n-3 PUFA on human health (Swanson, Block 
et al. 2012, Dyall 2015). 2) The risk of varying efficacy of D5D inhibitor under the different 
PUFA composition in foods. Here I used the HFD which contains high amount of LA and low 
or no amount of AA. But unlike in laboratory animals, human can choose a wide variety of 
foods and drinks, and the impact of dietary AA contents on the efficacy of D5D inhibition 
should be evaluated for further understanding of the therapeutic potential. Therefore, more 
experiments are necessary to elucidate the mechanism of action of D5D inhibition on anti-
obesity and anti-inflammatory potentials, and clear mitigation plans for potential concerns and 
problems are required.  
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In the second chapter, I investigated the influence of GPR40 agonist on insulin and glucagon 
secretion using rat and human isolated islets. At that time, the evidence that GPR40 agonist 
potentiates glucose-stimulated insulin secretion in human islets provided me confidence to 
proceed into the clinical trial. Consistent with my results, TAK-875 (Fasiglifam) showed 
glucose lowering efficacy in a 12 weeks phase 2 randomized, double-blind placebo control trial 
(Negoro, Sasaki et al. 2010, Burant, Viswanathan et al. 2012); unfortunately, the phase 3 trial 
was terminated due to the concerns of liver safety issue (Kaku, Enya et al. 2015). 
Natural substrates of GPR40 include saturated (C12-C16) and unsaturated (C18-C20) FFA, 
which act as full agonists of GPR40 to mediate glucose-stimulated insulin secretion from 
pancreatic β-cells and GLP-1 secretion from intestinal cells (Kotarsky, Nilsson et al. 2003, 
Flodgren, Olde et al. 2007). On the contrary, TAK-875 that I used here is now recognized as a 
partial agonist of GPR40 which binds to the different sites, and it is known that TAK-875 and 
FFA synergistically stimulate insulin secretion both in vitro and in vivo. (Yabuki, Komatsu et 
al. 2013). However, I have done all of experiments reported here under no FFA, and the 
addition of physiological concentration of FFA might better mimic the condition in human 
patients.  
Here, I pointed out the fact that effect of GPR40 agonist on glucagon secretion was different 
between rat and human islets. Although animal tissues are readily available, they sometimes 
failed to predict the results in the clinical trials (Akhtar 2015). And my results underscore the 
importance of confirming the investigation in human tissues for the drug discovery. 
In conclusion, fatty acids and their metabolites affect multiple pathways regulating and 
maintaining the physiological functions. And my researches reported here strongly suggested 
that basic research of the fatty acids-mediated signals on the onset of MS are worthy for the 
disease understanding and future drug discovery. 
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Table 1. Fatty acids mimetics proceeded into clinical trials 
 Target Endogenous ligands /substrates Efficacy / Role Mimetics that reached clinical use / trials 
Nuclear 
receptor 
PPARα 
Eicosanoids, unsaturated fatty 
acids 
energy homeostasis, fatty acids catabolism Fibrates, Saroglitazar, Elafibranor 
PPARγ 
glucose homeostasis, insulin sensitivity, anti-
inflammatory 
Glitazones, Saroglitazar, Elafibranor 
PPARδ 
energy homeostasis, thermogenesis, 
proliferation, tissue repair 
Elafibranor 
RXRs Unknown proliferation, differentiation, apoptosis Alitretinoin, Bexarotene 
RARs All-trans-retinoic acid, retinoids 
growth/development, proliferation, 
differentiation, apoptosis, inflammation  
Tazarotene, Adapalene 
FXR Bile acids (CDCA) 
bile acid homeostasis, lipid / glucose 
metabolism, liver inflammation 
Obeticholic acid 
Enzymes 
binding and 
metabolizing 
fatty acids 
SCD1 Stearyl-CoA, Palmitoyl-CoA 
endogenous synthesis of unsaturated fatty 
acids (oleyl-CoA, palmitoleyl-CoA) 
Aramchol 
COX-1 
Arachidonic acid 
cyclooxygenase pathway; formation of 
mediators of inflammation and pain, 
regulation of vascular tone and thrombocyte 
aggregation 
NSADs 
COX-2 NSAIDs, Coxibs 
5-LO Arachidonic acid, 15(S)-HETE 
lipoxygenase pathway; mediators of 
chemotaxis (LTA4, LXA4), pulmonary 
inflammation, allergy, bronchoconstriction  
Zileuton, Minocycline, Hyperforin 
GPCR 
FFAR1 (GP40) 
Mediucm- and long-chain fatty 
acids (C6-C22) 
incretin release, glucose-stimulated insulin 
secretion, tasting, inflammation 
Fasiglifam (TAK-875) 
PGD2 receptors 
(D1 and D2) 
PGD2 inflammation, pain, allergy Laropiprant, Vidupiprant 
PGE2 receptors (EP1-4) PGE2 
inflammation, pain 
Misoprostol 
PGF2α receptors 
(FPA and FPB) 
PGF2α Latanoprost 
PGI2 receptors (IP) PGI2 (prostacyclin) 
inflammation, pain, inhibition of platelet 
aggregation  
Beraprost, Treprostinil 
TXA2 receptors 
(TPα and TPβ) 
TXA2 
inflammation, pain, vasoconstriction, 
activation of platelet aggregation  
Seratrodast, Terutroban 
CysLT1 LTD4 ˃ LTC4>LTE4 
bronchoconstriction, chemotaxis, pulmonary 
inflammation  
Pranlukast, Zafirlukast, Montelukast 
Reference; J Med Chem. 2017 Jul 13;60(13):5235-5266 
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Table 2. Fatty acids composition of the high-fat diet (data are expressed as 
w/w%) 
 
  
Fatty acids D12492 D12079B 
C2 Acetic 0 0 
C4 Butyric 0 0.64 
C6 Caproic 0 0.38 
C8 Caprylic 0 0.22 
C10 Capric 0.01 0.50 
C12 Lauric 0.03 0.56 
C14 Myristic 0.36 2.00 
C14:1 Myristoleic 0 0.30 
C15  0.03 - 
C16 Palmitic 6.45 5.34 
C16:1 Palmitoleic 0.44 0.46 
C16:2  0 - 
C16:3  0 - 
C16:4  0 - 
C17  0.12 - 
C17:1  0 - 
C18 Stearic 3.48 2.44 
C18:1 Oleic 11.19 5.26 
C18:2 Linoleic 9.45 1.06 
C18:3 Linolenic 0.67 0.29 
C18:4 Stearidonic 0 0 
C20 Arachidic 0.05 0.19 
C20:1  0.19 0 
C20:2  0.26 - 
C20:3  0.04 - 
C20:4 Arachidonic 0.09 0 
C20:5 Eicosapentaenoic 0 0 
C21:5  0 - 
C22, Behenic 0 0 
C22:1 Erucic 0 0 
C22:4 Clupanodonic 0 0 
C22:5 Docosapentaenoic 0.03 0 
C22:6 Docosahexaenoic 0 0 
C24 Lignoceric 0 0 
C24:1  0 - 
   (%) 
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Table 3. In vitro IC50 values (nM) for fatty acid desaturases 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Compound Name Assay Methods Species D5D D6D D9D 
D5D inhibitor 
(Compound-326) 
Enzyme 
Rat 72 >10 000 >10 000 
(hepatic microsomes) 
Cell-based 
Human 22 >10 000 >10 000 
(HepG2) 
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Table 4. Sequences of TaqMan primers and probes 
Gene Forward primer Reverse primer Probe Accession 
number 
GPR40/FFA1 5'-
GCCCGCTTCAGCCTC
TCT-3' 
5'-
GAGGCAGCCCACGTA
GCA-3' 
FAM-5'-
TCTGCCCTTGGCCATCACAGCCT-3'-
TAMRA NM_005303 
GLP-1R 5'-
GCAGCCCTGAAGTG
GATGTATAG-3' 
5'-
CTCAGAGAGTCCTGGT
AGGAGAG-3' 
FAM-5'-
ACAGCCGCCCAGCAGCACCAGT-3'-
TAMRA NM_002062 
ABCC8 5'-
GCTGCCCATCGTTAT
GAGGG-3' 
5'-
GAATGTCCTTCCGCAC
CTGG-3' 
FAM-5'-
CCTCACCAACTACCAACGGCTCTGCG-
3'-TAMRA NM_000352 
GAPDH 5'-
TGAAGCAGGCGTCG
GAGG-3' 
5'-
GCTGTTGAAGTCAGAG
GAGACC-3' 
VIC-5'-
CCTCAAGGGCATCCTGGGCTACACTG-
3'-TAMRA NM_002046 
FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine;  
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Table 5. Clinical profiles of islet donors 
Experiment Donor No. Age(years) Sex(M/F) 
Gene analysis  
(Fig. 4) 
1 65 M 
2 55 M 
3 43 M 
4 52 M 
Hormone secretion assay  
(Table S3, Fig. 5) 
5 33 M 
6 54 - 
7 51 M 
8 57 F 
Intracellular Ca2+ 
measurements 
(Fig. 6) 
7 51 M 
8 57 F 
9 66 M 
M; Male, F; Female 
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Table 6. Summary of the results of static incubation assay in human islets (from 4 organ donors) 
 
  1 mM Glucose  16 mM Glucose 
 No.  GPR40 ago.   GPR40 ago. GLP-1 
(% of content/h)  - (1 μM)  - (0.3 μM) (1 μM) (3 μM) (10 nM) 
Insulin 5 0.27±0.02 0.35±0.02a  0.45±0.02d 0.83±0.11e 1.06±0.09e 0.78±0.06e 0.93±0.08a 
6 1.68±0.23 1.48±0.18  2.90±0.28c 4.79±0.42e 4.18e - 6.26±1.13 
7 0.44±0.03 0.45±0.10  1.76±0.18b - 1.78±0.14 - 2.76±0.21a 
8 0.05±0.01 0.04±0.00  0.29±0.01d 0.33±0.04 0.39±0.10 0.49±0.09 0.40±0.04 
Glucagon 5 2.49±0.26 2.44±0.24  1.62±0.10a 1.93±0.22 1.81±0.35 1.68±0.49 1.75±0.12 
6 0.81±0.19 0.56±0.11  0.59±0.02 0.84±0.14 0.38 - 0.46±0.10 
7 1.19±0.21 1.87±0.41  1.13±0.15 - 1.16±0.30 - 1.79±0.24 
8 1.02±0.19 0.95±0.11  0.72±0.13 0.79±0.20 0.68±0.11 0.77±0.10 0.59±0.11 
Human islets had been pre-incubated for 1 h at 1 mM glucose. Following the pre-incubation, these islets were incubated with the assay buffer 
containing 1 or 16 mM glucose with or without test substances for 1 h. Insulin (upper panel) and glucagon (lower panel) secretion were shown 
as % of content/h. Data are expressed as mean ± SEM (n=2-4). a p≤ 0.05, b p≤ 0.01 vs. 1 mM glucose control (Aspin Welch test), c p≤ 0.05, d p≤ 
0.01, vs. 16 mM glucose control (Student’s t-test). e p≤ 0.025, vs. 16 mM glucose control (one-tailed Williams’ test). 
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Figures 
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Fig. 1 The concept of metabolic domino 
Reference; Itoh H. Drugs Today (Barc). 2006; 42: Suppl C9-16 
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Fig. 2 Changes of insulin secretion during the progression T2DM 
Reference; Adapted from T2DM BASICS. International Diabetes Center: 2000. 
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Fig. 3 Classification and de novo fatty acids synthesis
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Fig. 4 Biosynthesis pathway of n-6 polyunsaturated fatty acids 
 
 
 
 
Fig. 5 Structure of D5D inhibitor; compound-326 
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Fig. 6 Effects of chronic treatment with D5D inhibitor on BW, calorie intake, 
and blood PD markers in DIO mice 
DIO mice (initial BW; 31.1±1.6 g) were treated with D5D inhibitor (0.1, 1, and 10 mg/kg), 30 
mg/kg sibutramine, or vehicle p.o. for 6 weeks. (A) Changes in BW from initial value. (B) 
Daily calorie intake during the study. (C) Changes in blood AA and DGLA concentrations 
after 6-week treatment. (D) Changes in the blood AA to DGLA ratio after 6-week treatment. 
Data are expressed as mean ± SEM (n=7). # p≤ 0.025 vs. DIO vehicle by Williams' test. § p≤ 
0.025 vs. DIO vehicle by Shirley-Williams test. * p≤ 0.05, ** p≤ 0.01 vs. DIO vehicle by 
Aspin-Welch test. ¶ p≤ 0.05, ¶¶ p≤ 0.01 vs. DIO vehicle by Student's t-test. 
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Fig. 7 Effects of chronic treatment with D5D inhibitor on blood EPA and DHA levels in DIO mice  
DIO mice (initial BW; 31.1±1.6 g) were treated with D5D inhibitor (0.1, 1, and 10 mg/kg), 30 mg/kg sibutramine, or vehicle p.o. for 6 weeks. (A) 
Changes in blood EPA concentrations after 6-week treatment. (B) Changes in blood DHA concentrations after 6-week treatment. NM stands for 
note measurable. Data are expressed as mean ± SEM (n=7). # p≤ 0.025 vs. DIO vehicle by Williams' test. ¶ p≤ 0.05, ¶¶ p≤ 0.01 vs. DIO vehicle 
by Student's t-test. 
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Fig. 8 Effects of chronic treatment with D5D inhibitor on plasma glucose 
and insulin during an OGTT, and HOMA-IR in DIO mice 
Oral glucose tolerance test (OGTT) was performed after chronic treatment with D5D inhibitor 
for 6 weeks in DIO mice. (A) Changes in plasma glucose levels. (B) Effect on plasma glucose 
AUC. (C) Changes in plasma insulin levels. (D) Effect on HOMA-IR. Data are expressed as 
mean ± SEM (n=7). § p≤ 0.025 vs. DIO vehicle by Shirley-Williams test. ¶ p≤ 0.05 vs. DIO 
vehicle by Student's t-test.
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Fig. 9 Effects of chronic treatment with D5D inhibitor on BW, calorie intake, and fat mass in DIO mice 
DIO mice were treated with 10 mg/kg D5D inhibitor, p.o., for 11 weeks. (A) Changes in BW. (B) Changes in daily calorie intake. (C) Weights of 
different body fat depots after 11-week treatment. Data are expressed as mean ± SEM (n=7). * p≤ 0.05, ** p≤ 0.01 vs. DIO vehicle by Aspin-
Welch test. ¶ p≤ 0.05, ¶¶ p≤ 0.01 vs. DIO vehicle by Student's t-test. 
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Fig. 10 Effect of chronic treatment with D5D inhibitor on energy 
expenditure in DIO mice 
Energy expenditure (EE) was monitored on days 1 (A), 8 (B), 15 (C), 21 (D), and 56 (E) during 
chronic dosing study indicated in Fig 9. Arrows indicate the timing of drug administration. 
Data are expressed as mean ± SEM (n=7). * p≤ 0.05 vs. DIO vehicle by Aspin-Welch test. ¶ 
p≤ 0.05 vs. DIO vehicle by Student's t-test. 
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Fig. 11 Effect of chronic treatment with D5D inhibitor on energy expenditure in DIO mice 
Daily energy expenditure (DEE) was monitored on days 1 (A), 8 (B), 15 (C), 21 (D), and 56 (E) during the study indicated in Fig 10. 
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Fig. 12 Effect of chronic treatment with D5D inhibitor on respiratory 
exchange ratio in DIO mice 
Respiratory exchange ratio (RER) was monitored on days 1 (A), 8 (B), 15 (C), 21 (D), and 56 
(E) during chronic dosing study indicated in Fig 9. (F) Changes in averaged RER. Arrows 
indicate the timing of drug administration. Data are expressed as mean ± SEM (n=7). 
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Fig. 13 Effects of D5D inhibitor on BW and AA and DGLA levels within 
the blood as well as liver in DIO mice 
Chronic administration of D5D inhibitor (10 mg/kg) significantly decreased BW in DIO mice. 
In these mice, increase in DGLA and decrease in AA in the blood as well as liver were observed 
after 6-week treatment with compound-326. (A) BW changes during the study. (B) BW at 
Day44. (C) Levels of AA and DGLA in the blood. (D) AA to DGLA ratio in the blood. (E) 
Levels of AA and DGLA in the liver. (F) AA to DGLA ratio in the liver. Data are expressed 
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as mean ± SEM (n=8-9). * p≤ 0.05, ** p≤ 0.01 vs. DIO vehicle by Aspin-Welch test. ¶¶ p≤ 
0.01 vs. DIO vehicle by Student's t-test. 
 
Fig. 14 Effects of chronic treatment with D5D inhibitor on PD markers and 
gene expression in WAT in DIO mice 
HFD-fed DIO mice were treated with D5D inhibitor (10 mg/kg), p.o. for 6 weeks. Mice fed a 
normal diet (ND) were used as normal reference. (A) Levels of AA and DGLA in epididymal 
adipose tissue. (B) AA to DGLA ratio in epididymal adipose tissue. RT-qPCR was performed 
in epididymal (C) and subcutaneous fat tissues (D) after 6-week treatment. Data are expressed 
as mean ± SEM (n=8-9). * p≤ 0.05, ** p≤ 0.01 vs. DIO vehicle by Aspin-Welch test. ¶ p≤ 0.05, 
¶¶ p≤ 0.01 vs. DIO vehicle by Student's t-test. 
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Fig. 15 Effects of chronic treatment with D5D inhibitor on blood and tissue EPA and DHA levels in HFD-fed mice 
HFD-fed mice were treated with D5D inhibitor (10 mg/kg), p.o. for 6 weeks. Mice fed a normal diet (ND) were used as normal reference. (A) 
Levels of EPA and DHA in the blood. (B) Levels of EPA and DHA in epididymal adipose tissue. (C) Levels of EPA and DHA in epididymal 
adipose tissue. NM stands for note measurable. Data are expressed as mean ± SEM (n=8-9). * p≤ 0.05 and ** p≤ 0.01 vs. DIO vehicle by Aspin-
Welch test. ¶¶ p≤ 0.01 vs. DIO vehicle by Student's t-test. 
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Fig. 16 Effects of D5D inhibitor on WAT gene expression in satellite DIO 
mice (Day32) 
In 6 weeks administration study of D5D inhibitor (10 mg/kg), satellite animals were prepared 
to evaluate the gene expression levels in epididymal fat at the intermediate point (day 32). Mice 
fed a HFD (D12079B; Research diets, Inc.) from 5 weeks of age were divided into 2 groups at 
the age of 8 weeks (11 animals per group), and were administered 10 mg/kg compound-326 or 
vehicle for 32 days. After the treatment period, mice were sacrificed and epididymal fats were 
harvested for mRNA analysis. (A) Compound-326 administration showed a trend towards BW 
loss in DIO mice. (B) RT-qPCR was performed in epididymal fat tissue after 32 days treatment. 
Data are expressed as mean ± SEM (n=11). * p≤ 0.05 vs. DIO vehicle by Aspin-Welch test. ¶¶ 
p≤ 0.01 vs. DIO vehicle by Student's t-test. 
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Fig. 17 Presumed mechanism of insulin secretion via GPR40 in pancreatic beta cell 
PLC, phospholipase C; IP3, inositol triphosphate; DAG, diacylglycerol; PKC, protein kinase C.
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Fig. 18 Effects of GPR40 agonist on insulin and glucagon secretion in rat 
islets 
Isolated rat islets were incubated with the assay buffer containing 1 or 16 mM glucose with or 
without test substances for 1 h. Insulin (A) and glucagon (B) secretion are quoted as % of 
content/h. Data are expressed as mean ± SEM (n=6). ** p≤ 0.01 vs. 1 mM glucose control 
(Aspin-Welch test), §§ p≤ 0.01 vs. 16 mM glucose control (Student’s t-test); # p≤ 0.025 vs. 16 
mM glucose control (one-tailed Williams’ test). 
88 
 
Fig. 19 Effect of GPR40 agonist on insulin secretion in perifused rat islets 
(A) Isolated rat islets were perifused with 1, 5 or 16 mM glucose with (○) or without GPR40 
agonist (3 µM; ●). The perifusate was collected every 1 or 2 min. Secreted insulin levels are 
shown as % of content/h. (B) AUC of secreted insulin during 1st and 2nd phase. Data are 
expressed as mean ±SEM (n=3). §§ p≤ 0.01 vs. 16 mM glucose control (Student’s t-test). AU 
stands for arbitrary units.  
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Fig. 20 Effects of GPR40 agonist on the intracellular Ca2+ response of single β and α cells within intact rat islets 
(A) Color image of rat islet located with the Ca2+-sensitive dye Fluo-4 at the beginning of Ca2+ recording. (B) Records of fluorescence intensity 
versus time from the cells indicated in panel A. Rβ1, 2 and Rα1, 2 are the representative [Ca2+]i response from single β- and α-cells, respectively, 
exposed to 1 mM glucose, 16 mM glucose and 16 mM glucose plus 3 µM GPR40 agonist as indicated above the traces. (C) Summary of the [Ca2+]i 
response from 43 single β-cells within 3 independent islets and expressed as mean ±SEM (D) Summary of [Ca2+]i response from 23 single α-cells 
within 3 independent islets, expressed as mean ±SEM. ** p ≤ 0.01 vs. 1 or 16 mM glucose control (Aspin-Welch test); §§ p≤ 0.01 vs. 16 mM 
glucose control (Student’s t-test). AU stands for arbitrary units. 
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Fig. 21 Comparison of gene expression levels of GPR40, GLP-1R and SUR1 in human islets 
The relative mRNA expressions for an internal control GAPDH are expressed as mean and SEM (n=4). 
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Fig. 22 Effects of GPR40 agonist on insulin and glucagon secretion in 
human islets 
The mean value of hormone levels for 1 mM glucose control equals 100%, and all data are 
expressed as percentage from basal. Data are expressed as mean ± SEM (n=6-13). * p≤ 0.05 vs. 
1 mM glucose control (Aspin-Welch test); § p≤ 0.05 vs. 1 mM glucose control, §§ p≤ 0.01 vs. 
16 mM glucose control (Student’s t-test); # p≤ 0.025 vs.16 mM glucose control (one-tailed 
Williams’ test). Data of the separate experiments (individual donors) are provided in table 6. 
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Fig. 23 Effects of GPR40 agonist on the intracellular Ca2+ response of single 
β- and α-cells within intact human islets 
(A) Color image of human islet located with the Ca2+-sensitive dye Fluo-4 at the beginning of 
Ca2+ recording. (B) Records of fluorescence intensity versus time from the cells indicated in 
panel A. Hβ1, 2 are representative [Ca2+]i response from β-cells exposed to 1 mM glucose, 16 
mM glucose, and 16 mM glucose plus 3 µM GPR40 agonist as indicated above the traces. (C) 
Summary of the [Ca2+]i response from 146 single β-cells within 15 independent islets, 
expressed as mean ± SEM. ** p ≤ 0.01. 
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Fig. 24 Individual data of [Ca2+]i response to 3 µM GPR40 agonist in three non-diabetic donors 
The data are collected from 63 β-cells from 6 islets from donor 7, 8 and 9, respectively. Data are expressed as mean ±SEM (n=63). 
 
